Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia.
Recombinant activated factor VII (rFVIIa) is a powerful hemostatic agent developed for use in hemophilia. It has been used increasingly in life-threatening hemorrhage in a variety of other settings in which conventional medical or surgical therapy is unsuccessful. This report describes the successful use of rFVIIa for pulmonary hemorrhage due to a focal bleeding source in a regional hospital where bronchial artery embolization or surgery were not available. rFVIIa may be a useful temporizing measure in the unstable patient with pulmonary hemorrhage without coagulopathic bleeding when conventional treatment is not immediately available.
Macdonald
James A
JA
Critical Care Research Group, The Prince Charles Hospital, Chermside QLD, Australia.
Fraser
John F
JF
Foot
Carole L
CL
Tran
Khoa
K
D001995:Bronchography; D001999:Bronchoscopy; D003937:Diagnosis, Differential; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D005500:Follow-Up Studies; D006469:Hemoptysis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000150:complications* / Q000175:diagnosis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa